STRAD Inhibitors
STRAD inhibitors represent a diverse class of compounds that exert their effects on the STRAD protein indirectly by influencing specific cellular pathways. These inhibitors exploit various signaling cascades, finely tuned cellular processes, and key regulatory proteins to modulate the activity of STRAD. One notable example is Rapamycin, a macrolide compound that functions as an mTOR inhibitor. Rapamycin binds to FKBP12, inhibiting the mTORC1 complex and disrupting downstream signaling cascades. This disruption indirectly impacts STRAD by suppressing pathways dependent on mTOR, such as protein synthesis and autophagy.
Another significant member of this class is LY294002, a potent PI3-kinase inhibitor. LY294002 disrupts the PI3K/AKT/mTOR pathway, indirectly affecting STRAD by inhibiting the upstream PI3-kinase and subsequently reducing AKT activation. The modulation of STRAD occurs through downstream targets of the PI3K pathway. Similarly, Sorafenib, a multi-kinase inhibitor targeting Raf kinases, influences STRAD by disrupting the Raf/MEK/ERK pathway. This alteration in the signaling cascade results in the indirect modulation of STRAD through ERK phosphorylation. Wortmannin, SB203580, U0126, SP600125, PD98059, AZD5363, GDC-0941, SB202190, and Axitinib further exemplify this class, each impacting distinct signaling pathways such as PI3K/AKT, MAPK/ERK, JNK, and tyrosine kinases. These inhibitors induce downstream effects on STRAD by altering the phosphorylation status of key proteins within their respective pathways. The collective action of STRAD inhibitors thus highlights the intricate network of cellular processes that can be harnessed to indirectly modulate the activity of this crucial protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, a macrolide compound, functions as an mTOR inhibitor. It binds to the FKBP12 protein and inhibits the mTORC1 complex, disrupting the downstream signaling cascade. By blocking mTOR, rapamycin indirectly modulates STRAD through the suppression of pathways dependent on mTOR, influencing cellular processes like protein synthesis and autophagy. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent PI3-kinase inhibitor that disrupts the PI3K/AKT/mTOR pathway. This compound indirectly affects STRAD by inhibiting the upstream PI3-kinase, leading to reduced AKT activation. Consequently, downstream targets of the PI3K pathway, including STRAD, experience decreased activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets Raf kinases. By inhibiting the Raf/MEK/ERK pathway, sorafenib indirectly influences STRAD, as this protein is regulated by ERK phosphorylation. The compound disrupts the downstream signaling events, ultimately modulating STRAD activity through the Raf/MEK/ERK axis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3-kinase, disrupting the PI3K/AKT signaling pathway. This inhibition leads to downstream effects on various cellular processes, including STRAD modulation. The compound indirectly influences STRAD by altering the phosphorylation status of key signaling components within the PI3K pathway, resulting in the modulation of STRAD activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 functions as a specific inhibitor of p38 MAP kinase, impacting the p38 MAPK signaling pathway. By inhibiting p38, this compound indirectly influences STRAD, as p38 MAP kinase is involved in the regulation of STRAD expression. SB203580 alters the cellular milieu by disrupting p38-mediated signaling events, ultimately modulating STRAD activity through its regulatory network. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, targeting the JNK signaling pathway. By inhibiting JNK, this compound indirectly influences STRAD, as JNK is involved in the regulation of STRAD expression. SP600125 alters the cellular signaling landscape by disrupting JNK-mediated events, ultimately modulating STRAD activity through its regulatory network. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective MEK inhibitor, disrupting the MAPK/ERK pathway. Through its action on MEK, PD98059 indirectly modulates STRAD by interfering with the MAPK/ERK signaling cascade. The compound alters the phosphorylation status of proteins within this pathway, leading to downstream effects on STRAD activity and expression. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is a pan-AKT kinase inhibitor, disrupting the PI3K/AKT/mTOR pathway. By inhibiting AKT, this compound indirectly influences STRAD, as AKT is an upstream regulator of STRAD activity. AZD5363 alters the phosphorylation status of key signaling components within the PI3K pathway, resulting in downstream effects on STRAD modulation. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a selective PI3-kinase inhibitor, disrupting the PI3K/AKT/mTOR pathway. By inhibiting PI3-kinase, this compound indirectly influences STRAD, as PI3-kinase is upstream in the regulation of STRAD activity. GDC-0941 alters the phosphorylation status of key signaling components within the PI3K pathway, resulting in downstream effects on STRAD modulation. | ||||||